Literature DB >> 12561005

Treatment of esophagogastric tumors.

R Lambert1.   

Abstract

Esophageal and gastric tumors are often considered as a single group: they share similar symptoms - upper GI endoscopy with a flexible video-endoscope is the gold standard procedure of detection - similar techniques of endotherapy for cure or palliation are offered for both types of tumors. When the endoscopic procedure is performed for a superficial cancer or its precursors, with a curative intent, endoscopic mucosal resection (EMR) is generally preferred to mucosal ablation with a thermal (Nd:YAG) or non-thermal (photodynamic therapy) procedure. In addition to esophageal squamous cell cancer and gastric cancer, new indications of EMR arise in the Barrett esophagus. Guidelines for safe indications concern diameter, polypoid or non polypoid morphology with the subtypes elevated, flat and depressed, and depth of invasion. A superficial invasion in the sub-mucosa is a relative contra-indication in the esophagus, but not in the stomach. The technique of EMR is now codified with an injection into the submucosa for lifting the lesion and either suction with a cap, grasping with a forceps if a 2 channel instrument is used, or tissue incision with a needle knife. En bloc, gives better results than piecemeal resection. The most frequent complication is bleeding. When legitimate indications are respected, the results of EMR are equivalent to those of surgical resection and have reached the consensus level. The major indication in palliation is the relief of dysphagia from malignant esophageal obstruction. Increased indications are proposed for malignant pyloric obstruction. Multiple models of metal expandable and coated stents with appropriate balance between rigidity and flexibility (nitinol alloy) and enough expansive radial force are now offered. After stenting the survival period is short and there is a toll of complications.

Entities:  

Mesh:

Year:  2003        PMID: 12561005     DOI: 10.1055/s-2003-37016

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  7 in total

1.  Spectrum of final pathological diagnosis of gastric adenoma after endoscopic resection.

Authors:  Kwan Woo Nam; Kyu Sang Song; Heon Young Lee; Byung Seok Lee; Jae Kyu Seong; Seok Hyun Kim; Hee Seok Moon; Eaum Seok Lee; Hyun Yong Jeong
Journal:  World J Gastroenterol       Date:  2011-12-21       Impact factor: 5.742

2.  [Mucosectomy as sufficient therapy for early squamous cell].

Authors:  M Jung
Journal:  Chirurg       Date:  2005-11       Impact factor: 0.955

Review 3.  [Palliative treatment options for esophageal and gastric cancer].

Authors:  A Eickhoff; R Jakobs; J F Riemann
Journal:  Internist (Berl)       Date:  2004-07       Impact factor: 0.743

4.  Clinical outcomes and patency of self-expanding metal stents in patients with malignant upper gastrointestinal obstruction.

Authors:  Jong Pil Im; Jung Mook Kang; Sang Gyun Kim; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

5.  Endoscopic characteristics of gastric adenomas suggesting carcinomatous transformation.

Authors:  Min Kyu Jung; Seong Woo Jeon; Soo Young Park; Chang Min Cho; Won Young Tak; Young Oh Kweon; Sung Kook Kim; Yong Hwan Choi; Han Ik Bae
Journal:  Surg Endosc       Date:  2008-04-10       Impact factor: 4.584

6.  What are the risk factors for residual tumor cells after endoscopic complete resection in gastric epithelial neoplasia?

Authors:  Gak Won Yun; Jie-Hyun Kim; Yong Chan Lee; Sang Kil Lee; Sung Kwan Shin; Jun Chul Park; Hyun Soo Chung; Jae Jun Park; Young Hoon Youn; Hyojin Park
Journal:  Surg Endosc       Date:  2015-02       Impact factor: 4.584

7.  Fluoroscopic guidance biopsy for severe anastomotic stricture after esophagogastrostomy of esophageal carcinoma: A STROBE-compliant article.

Authors:  Yonghua Bi; Jindong Li; Hongmei Chen; Xinwei Han; Gang Wu; Jianzhuang Ren
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.